GOLDMAN SACHS GROUP INC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$8,404,518
-55.8%
407,393
-36.8%
0.00%
-50.0%
Q2 2023$19,031,412
+44.2%
644,914
+12.6%
0.00%
+33.3%
Q1 2023$13,198,303
-38.5%
572,843
-25.7%
0.00%
-40.0%
Q4 2022$21,454,080
-4.0%
771,452
+5.9%
0.01%0.0%
Q3 2022$22,352,000
+80.5%
728,272
+73.1%
0.01%
+66.7%
Q2 2022$12,382,000
-5.3%
420,742
+3.6%
0.00%0.0%
Q1 2022$13,069,000
-28.7%
406,228
-1.1%
0.00%
-25.0%
Q4 2021$18,320,000
-65.6%
410,764
-61.1%
0.00%
-63.6%
Q3 2021$53,304,000
+10.0%
1,056,558
+71.0%
0.01%0.0%
Q2 2021$48,461,000
+31.0%
617,818
-4.6%
0.01%
+22.2%
Q1 2021$36,992,000
-37.1%
647,851
-7.8%
0.01%
-40.0%
Q4 2020$58,833,000
+224.8%
702,394
+38.9%
0.02%
+200.0%
Q3 2020$18,113,000
+228.8%
505,542
+121.9%
0.01%
+150.0%
Q2 2020$5,509,000
+139.5%
227,809
+73.4%
0.00%
+100.0%
Q1 2020$2,300,000
+31.0%
131,365
+30.3%
0.00%
Q4 2019$1,756,000
+10.1%
100,787
-3.2%
0.00%
Q3 2019$1,595,000
-20.0%
104,087
+8.4%
0.00%
-100.0%
Q2 2019$1,994,000
-20.0%
96,058
-10.5%
0.00%0.0%
Q1 2019$2,491,000
+76.5%
107,294
+57.1%
0.00%
Q4 2018$1,411,000
+432.5%
68,278
+460.7%
0.00%
Q3 2018$265,000
-67.5%
12,178
-77.3%
0.00%
Q2 2018$816,000
-68.7%
53,530
-59.6%
0.00%
-100.0%
Q1 2018$2,610,000
+19.2%
132,535
-5.3%
0.00%0.0%
Q4 2017$2,189,000139,9760.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Crestline Management, LP 7,705,039$343,645,00025.68%
Casdin Capital, LLC 1,500,000$66,900,0001.89%
Flagship Pioneering Inc. 2,619,968$116,851,0001.81%
SECTORAL ASSET MANAGEMENT INC 189,600$8,456,0001.27%
Integral Health Asset Management, LLC 100,000$4,460,0001.23%
Temasek Holdings (Private) Ltd 5,369,487$239,479,0000.86%
Goldstream Capital Management Ltd 78,418$3,497,0000.86%
Yiheng Capital Management, L.P. 335,184$14,949,0000.76%
GILDER GAGNON HOWE & CO LLC 2,900,114$129,345,0000.74%
Artal Group S.A. 600,000$26,760,0000.73%
View complete list of DENALI THERAPEUTICS INC shareholders